Standard Inventory vs Non Current Assets Total Analysis
LAB Stock | USD 1.94 0.08 3.96% |
Standard Biotools financial indicator trend analysis is much more than just breaking down Standard Biotools prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Standard Biotools is a good investment. Please check the relationship between Standard Biotools Inventory and its Non Current Assets Total accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.
Inventory vs Non Current Assets Total
Inventory vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Standard Biotools Inventory account and Non Current Assets Total. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Standard Biotools' Inventory and Non Current Assets Total is 0.87. Overlapping area represents the amount of variation of Inventory that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Standard Biotools, assuming nothing else is changed. The correlation between historical values of Standard Biotools' Inventory and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory of Standard Biotools are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Inventory i.e., Standard Biotools' Inventory and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | 0.87 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Inventory
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Standard Biotools' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Standard Biotools current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.At present, Standard Biotools' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 102.8 M, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 3.8M | 4.3M | 4.6M | 4.5M | Depreciation And Amortization | 23.2M | 15.0M | 15.2M | 10.8M |
Standard Biotools fundamental ratios Correlations
Click cells to compare fundamentals
Standard Biotools Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Standard Biotools fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 264.8M | 324.8M | 275.2M | 390.3M | 323.1M | 228.8M | |
Short Long Term Debt Total | 60.0M | 95.4M | 111.6M | 102.7M | 98.2M | 104.4M | |
Other Current Liab | 12.7M | 25.6M | 12.2M | 10.5M | 19.3M | 12.6M | |
Total Current Liabilities | 32.8M | 54.2M | 49.6M | 43.4M | 109.3M | 114.8M | |
Total Stockholder Equity | 153.6M | 139.1M | 94.6M | (81.5M) | 163.2M | 171.4M | |
Property Plant And Equipment Net | 12.9M | 55.6M | 65.2M | 59.5M | 54.9M | 57.6M | |
Current Deferred Revenue | 11.8M | 13.5M | 15.5M | 14.4M | 11.6M | 7.8M | |
Net Debt | 38.3M | 26.9M | 83.2M | 21.3M | 46.5M | 49.6M | |
Retained Earnings | (623.6M) | (676.8M) | (736.0M) | (926.1M) | (1.0B) | (950.7M) | |
Accounts Payable | 6.5M | 9.2M | 10.6M | 7.9M | 9.2M | 5.5M | |
Cash | 21.7M | 68.5M | 28.5M | 81.3M | 51.7M | 43.2M | |
Non Current Assets Total | 168.7M | 207.1M | 203.1M | 181.5M | 164.9M | 124.5M | |
Non Currrent Assets Other | 5.5M | 4.7M | 3.7M | 3.1M | 2.3M | 4.4M | |
Cash And Short Term Investments | 58.6M | 68.5M | 28.5M | 165.8M | 114.9M | 72.5M | |
Net Receivables | 19.0M | 25.4M | 18.3M | 17.3M | 19.7M | 15.4M | |
Common Stock Shares Outstanding | 66.8M | 72.0M | 75.8M | 78.3M | 79.2M | 83.1M | |
Short Term Investments | 5.1M | 0.0 | 37.0M | 84.5M | 63.2M | 35.1M | |
Liabilities And Stockholders Equity | 264.8M | 324.8M | 275.2M | 390.3M | 323.1M | 228.8M | |
Non Current Liabilities Total | 78.4M | 131.5M | 131.1M | 428.3M | 50.5M | 48.0M | |
Inventory | 13.9M | 19.7M | 20.8M | 21.5M | 20.5M | 13.6M | |
Other Current Assets | 4.6M | 4.0M | 4.5M | 4.3M | 3.1M | 2.8M | |
Other Stockholder Equity | 777.8M | 815.6M | 831.4M | 846.4M | 854.8M | 467.6M | |
Total Liab | 111.2M | 185.7M | 180.6M | 471.8M | 159.9M | 205.2M | |
Total Current Assets | 96.1M | 117.7M | 72.1M | 208.8M | 158.2M | 104.3M | |
Accumulated Other Comprehensive Income | (582K) | 112K | (907K) | (1.9M) | (2.2M) | (2.1M) | |
Short Term Debt | 1.8M | 5.9M | 9.9M | 9.4M | 68.2M | 71.6M | |
Common Stock | 70K | 75K | 77K | 80K | 83K | 87.2K | |
Intangible Assets | 46.2M | 40.2M | 27.9M | 12.6M | 1.4M | 1.3M | |
Other Assets | 2.6M | 2.7M | 2.4M | 3.1M | 2.8M | 3.4M | |
Long Term Debt | 53.8M | 54.2M | 64.2M | 62.8M | 4.0M | 3.8M | |
Long Term Debt Total | 53.8M | 54.2M | 64.2M | 62.8M | 56.5M | 91.1M | |
Capital Surpluse | 777.8M | 815.6M | 831.4M | 847.0M | 974.1M | 774.5M | |
Cash And Equivalents | 5.0M | 20.7M | 28.5M | 81.3M | 93.5M | 98.2M | |
Property Plant Equipment | 12.9M | 55.6M | 65.2M | 59.5M | 68.5M | 36.3M | |
Other Liab | 20.2M | 39.1M | 29.3M | 20.2M | 23.2M | 28.7M | |
Net Tangible Assets | 372K | (9.7M) | (41.0M) | 110.9M | 127.6M | 134.0M | |
Net Invested Capital | 207.4M | 193.3M | 165.6M | (16.6M) | (84.5M) | (80.3M) | |
Capital Stock | 70K | 75K | 77K | (81.5M) | 83K | 87.2K | |
Non Current Liabilities Other | 573K | 1.3M | 882K | 961K | 1.1M | 888.5K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.558 | Quarterly Revenue Growth (0.14) | Return On Assets (0.15) | Return On Equity (0.37) |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.